On 4/6/2017, Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) closed at $8.53 in last trading day. After noting the initial trading entry at $8.66, it reached to a day’s high of $8.68 and moved to a day’s low of $8.30. The recent daily volume was 980.72 thousand as contrast to it’s an average volume of 1.44 million.
The last close of the Progenics Pharmaceuticals Inc. stock reflects that it traded -19.83% from its 50-day moving average of $10.64. The stock traded above +0.44% to its 200-day MA of $8.49. Furthermore, it moved lower -27.22% from its 52-week high of $11.72 and +113.25% up from $4.00, which is 52-week low of the stock.
Progenics Pharmaceuticals, Inc.’s (PGNX) moved with shift of -11.15% in the past week. Over the last three months, the shares of the company have changed -2.29% and performed 19.80% over the last six months. The stock currently has Monthly Volatility of 5.01% and Weekly Volatility of 4.76%.
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.
Canadian Solar Inc. (NASDAQ:CSIQ) finalized the last transaction at value of $12.65, with a daily change of +2.85% or +0.35 points. The company maintained volume of 931.9 thousand shares. In past trading day, the stock hit the maximum price of $12.73 and touched to minimum value of $12.16. It has a market cap of $ 731.25M.
As of last trade close, the stock is trading downside -35.62% from its one year high of $19.65 and moved +23.41% upward from $10.25, which is one year low of the stock.
The stock traded below -4.82% from its 50-day moving average of $13.29. Furthermore, the stock moved -2.57% to its 200-day MA of $ 12.98.
During the last month, Canadian Solar Inc.’s (CSIQ) has changed -5.81% and performed -14.00% over the last 6 months. The mean rating score for this stock is at 3.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 4.04% in recent month and observed Weekly Volatility of 3.95%.
Canadian Solar Inc., together with its subsidiaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products primarily under the Canadian Solar brand name. The company operates through Module, Energy Development, and Electricity Generation segments. Its products include various solar modules that are used in residential, commercial, and industrial solar power generation systems. The company also provides specialty solar products consisting of Andes Solar Home System, an off-grid solar system, designed to provide an economical source of electricity to homes and communities without access to grid; and Maple Solar System, a clean energy solution for families, as well as solar system kits, which are a ready-to-install packages, such as inverters, racking system, and other accessories. In addition, it develops, builds, and sells solar power projects; performs the engineering, procurement, and construction (EPC) work for the solar projects; and offers operation and maintenance services that include inspection, repair, and replacement of plant equipment, site management, and administrative support services. It offers its products to distributors, system integrators, project developers, and installers/EPC companies. The company has operations in North America, South America, Europe, Africa, the Middle East, Australia, and Asia. Canadian Solar Inc. was founded in 2001 and is based in West Guelph, Canada.